Bullfrog AI (BFRG) Registration filing summary

Company overview and business model

• AI/ML-focused drug development business; bfLEAP analyzes complex preclinical and clinical data to support precision medicine, improve development success, and identify opportunities to rescue failed drugs.

• Platform originated at Johns Hopkins University Applied Physics Laboratory; exclusive worldwide licenses cover patents, algorithms, know-how, and related intellectual property, with royalties and milestone-related payments.

• Strategy combines AI/ML analysis services, collaborations with biopharma and research institutions, and internal development or licensing of drug assets; has completed its first commercial service contract and a preclinical study for its Mebendazole prodrug program.

• Plans to expand bfLEAP, pursue proprietary health-data partnerships, and obtain rights to later-stage clinical assets for potential drug rescue; clinical execution depends on external partners and suppliers.

Financial performance and metrics

• No revenue generated to date; operating losses have accumulated since inception, and losses are expected to continue and potentially increase as drug development expands.

• Operating expenses are expected to increase in the near future; profitability depends on successful development, regulatory approval, and commercialization of drug candidates.

• At Aug. 2, 2024, common stock closed at $3.05; non-affiliate public float market value was $15,986,179, based on 5,241,370 shares.

Use of proceeds and capital allocation

• Net proceeds are intended for general corporate purposes, including R&D and clinical trials, unless otherwise specified in an offering supplement.

• Prior IPO proceeds and February 2024 offering proceeds supported R&D, staffing, marketing, collaborations, and retirement of notes and other accrued obligations.